{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:01:26Z","timestamp":1791820886791,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["PPM-00604-17"],"award-info":[{"award-number":["PPM-00604-17"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["304632\/2019-8"],"award-info":[{"award-number":["304632\/2019-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305592\/2017-3"],"award-info":[{"award-number":["305592\/2017-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["309252\/2021-0"],"award-info":[{"award-number":["309252\/2021-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vhri.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T01:05:24Z","timestamp":1714093524000},"page":"100985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies"],"prefix":"10.1016","volume":"42","author":[{"given":"Andr\u00e9","family":"Motta-Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9lia","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f4nica","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.vhri.2024.02.002_bib1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.vhri.2024.02.002_bib2","author":"Bodamer"},{"issue":"5","key":"10.1016\/j.vhri.2024.02.002_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.002_bib4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"issue":"7","key":"10.1016\/j.vhri.2024.02.002_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.vhri.2024.02.002_bib6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/0883073807305666","article-title":"Molecular functions of the SMN complex","volume":"22","author":"Kolb","year":"2007","journal-title":"J\u00a0Child Neurol"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.002_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.vhri.2024.02.002_bib8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.vhri.2024.02.002_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.vhri.2024.02.002_bib10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"suppl 15","key":"10.1016\/j.vhri.2024.02.002_bib13","first-page":"96","article-title":"SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"2240","author":"Oskoui","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.vhri.2024.02.002_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.vhri.2024.02.002_bib15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vhri.2024.02.002_bib16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","article-title":"Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1","volume":"37","author":"Bischof","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.vhri.2024.02.002_bib17","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s12325-023-02520-2","article-title":"A\u00a0critical appraisal of matching-adjusted indirect comparisons in spinal muscular atrophy","volume":"40","author":"Jiang","year":"2023","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.vhri.2024.02.002_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/cer-2021-0216","article-title":"How does risdiplam compare with other treatments for types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison","volume":"11","author":"Ribero","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"8","key":"10.1016\/j.vhri.2024.02.002_bib25","first-page":"1","article-title":"CADTH reimbursement recommendation risdiplam (Evrysdi)","volume":"1","year":"2021","journal-title":"Can J Health Technol"},{"key":"10.1016\/j.vhri.2024.02.002_bib26","series-title":"Pharmacoeconomic Report: Onasemnogene Abeparvovec (Zolgensma) for the Treatment of Pediatric Patients With 5q Spinal Muscular Atrophy (SMA) With Bi-allelic Mutations in the Survival Motor Neuron 1","year":"2021"},{"issue":"8","key":"10.1016\/j.vhri.2024.02.002_bib27","first-page":"1","article-title":"CADTH reimbursement recommendation nusinersen (Spinraza)","volume":"2","year":"2022","journal-title":"Can J Health Technol"},{"key":"10.1016\/j.vhri.2024.02.002_bib31","author":"Blok"},{"key":"10.1016\/j.vhri.2024.02.002_bib32","author":"Cumbers"},{"key":"10.1016\/j.vhri.2024.02.002_bib33","author":"Goddard"},{"key":"10.1016\/j.vhri.2024.02.002_bib34","author":"Sleeman"},{"key":"10.1016\/j.vhri.2024.02.002_bib35","author":"Stein"},{"key":"10.1016\/j.vhri.2024.02.002_bib36","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.vhri.2024.02.002_bib38","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"issue":"3","key":"10.1016\/j.vhri.2024.02.002_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14737167.2018.1443810","article-title":"Cost-effectiveness thresholds: methods for setting and examples from around the world","volume":"18","author":"Santos","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.002_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.002_bib42","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost\u2013effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"9","key":"10.1016\/j.vhri.2024.02.002_bib43","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.vhri.2024.02.002_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol Assess"},{"issue":"9","key":"10.1016\/j.vhri.2024.02.002_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2017.08.2466","article-title":"The efficiency path to universal health coverage: derivation of cost-effectiveness thresholds based on health expenditures and life expectancy. Updated country-level estimates for 194 countries","volume":"20","author":"Pichon-Riviere","year":"2017","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.002_bib46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres","year":"2018","journal-title":"Health Econ"},{"issue":"8","key":"10.1016\/j.vhri.2024.02.002_bib47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"12","key":"10.1016\/j.vhri.2024.02.002_bib48","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.15.164418","article-title":"Cost\u2013effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.vhri.2024.02.002_bib51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.healthpol.2022.01.013","article-title":"Promoting innovation while controlling cost: the UK\u2019s approach to health technology assessment","volume":"126","author":"Anderson","year":"2022","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"issue":"7","key":"10.1016\/j.vhri.2024.02.002_bib52","first-page":"793","article-title":"Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold","volume":"25","author":"Garrison","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","article-title":"A\u00a0web-based tool for adjusting costs to a specific target currency and price year","volume":"6","author":"Shemilt","year":"2010","journal-title":"Evid Policy"},{"issue":"6","key":"10.1016\/j.vhri.2024.02.002_bib54","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"10","key":"10.1016\/j.vhri.2024.02.002_bib55","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2024.02.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2020.04.810","article-title":"Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment in Japan","volume":"23","author":"Dean","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib57","article-title":"An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)","volume":"9","author":"Dean","year":"2021","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib58","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"6","key":"10.1016\/j.vhri.2024.02.002_bib59","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2024.02.002_bib60","article-title":"Cost-utility analysis of risdiplam compared with onasemnogene abeparvovec in spinal muscular atrophy type 1. In brussels","author":"Bischof","year":"2022","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.vhri.2024.02.002_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.09.2381","article-title":"Cost-effectiveness and budget impact of onasemnogene abeparvovec for spinal muscular atrophy type 1: post-hoc analysis of a model developed by ICER","volume":"22","author":"Dabbous","year":"2019","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.vhri.2024.02.002_bib62","first-page":"6544","article-title":"Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia","volume":"269","author":"Wang","year":"2022","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.vhri.2024.02.002_bib63","article-title":"Improved quality of life and life-years in patients with infantile-onset SMA following treatment with nusinersen","volume":"22","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2024.02.002_bib64","article-title":"Improved quality of life for patients and caregivers among patients with later-onset SMA following treatment with nusinersen","volume":"22","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2021.11.499","article-title":"Cost-effectiveness of risdiplam versus nusinersen for treating patients with spinal muscular atrophy type 1 in China","volume":"25","author":"Hu","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2024.02.002_bib66","article-title":"Cost-effectiveness of risdiplam in treating patients with type 1 spinal muscular atrophy in the United States","volume":"28","author":"Meyer","year":"2022","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.vhri.2024.02.002_bib67","author":"Thokala"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","article-title":"Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US","volume":"18","author":"Thokala","year":"2020","journal-title":"Cost Eff Resour Alloc C E"},{"key":"10.1016\/j.vhri.2024.02.002_bib69","series-title":"Pharmacoeconomic Review Report: Nusinersen (Spinraza) for the Treatment of Patients With 5q. Ottawa","year":"2019"},{"key":"10.1016\/j.vhri.2024.02.002_bib71","series-title":"Canadian Agency for Drugs and Technologies in Health [CADTH Canadian Drug Expert Committee Recommendation]: onasemnogene abeparvovec (Zolgensma). London","year":"2021"},{"key":"10.1016\/j.vhri.2024.02.002_bib89","series-title":"Cost-effectiveness of Nusinersen (Spinraza) for the treatment of 5q spinal muscular atrophy (SMA)","year":"2017"},{"issue":"12","key":"10.1016\/j.vhri.2024.02.002_bib90","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40273-020-00954-y","article-title":"Informing a cost-effectiveness threshold for health technology assessment in China: a marginal Productivity approach","volume":"38","author":"Ochalek","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.002_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.002_bib75","first-page":"207","article-title":"Economic evaluation of antipsychotics for the treatment of schizophrenia: a systematic review avalia\u00e7\u00e3o econ\u00f4mica de antipsic\u00f3ticos para o tratamento da esquizofrenia: uma revis\u00e3o sistem\u00e1tica","volume":"9","author":"Santos","year":"2017","journal-title":"J\u00a0Bras Econ Sa\u00fade"},{"issue":"7400","key":"10.1016\/j.vhri.2024.02.002_bib76","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vhri.2024.02.002_bib77","author":"Cassidy"},{"key":"10.1016\/j.vhri.2024.02.002_bib78","author":"Betts"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.002_bib79","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5152\/eurjrheum.2018.18162","article-title":"Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison","volume":"5","author":"Maksymowych","year":"2018","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.002_bib80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE","volume":"38","author":"Phillippo","year":"2016","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.002_bib81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1744133116000049","article-title":"Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use","volume":"11","author":"Culyer","year":"2016","journal-title":"Health Econ Policy Law"},{"key":"10.1016\/j.vhri.2024.02.002_bib82","author":"Paulden"},{"key":"10.1016\/j.vhri.2024.02.002_bib83","series-title":"Reflecting affordability in cost-effectiveness analysis through appropriate measures of opportunity cost","author":"Sculpher","year":"2017"},{"issue":"2","key":"10.1016\/j.vhri.2024.02.002_bib84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0047-2727(73)90002-9","article-title":"Critical ratios and efficient allocation","volume":"2","author":"Weinstein","year":"1973","journal-title":"J\u00a0Public Econ"},{"issue":"1","key":"10.1016\/j.vhri.2024.02.002_bib85","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/23288604.2015.1124172","article-title":"Using cost-effectiveness evidence to inform decisions as to which health services to provide","volume":"2","author":"Cairns","year":"2016","journal-title":"Health Syst Reform"},{"issue":"7638","key":"10.1016\/j.vhri.2024.02.002_bib86","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/bmj.39434.500185.25","article-title":"Value based pricing for NHS drugs: an opportunity not to be missed?","volume":"336","author":"Claxton","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vhri.2024.02.002_bib87","series-title":"Health technology assessment and health policy today: a multifaceted view of their unstable crossroads","first-page":"1","author":"Llano-Se\u00f1ar\u00eds","year":"2015"},{"issue":"4","key":"10.1016\/j.vhri.2024.02.002_bib88","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0167-6296(93)90004-X","article-title":"Equity and equality in health and health care","volume":"12","author":"Culyer","year":"1993","journal-title":"J\u00a0Health Econ"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:33:31Z","timestamp":1762605211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":74,"alternative-id":["S2212109924000153"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.02.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100985"}}